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Abstract	 SA Fam Pract 2010;52(5):451-458
Background: Although private sector doctors are the backbone of treatment service in many countries, caring for patients 
with HIV entails a whole new set of challenges and difficulties. The few studies done on the quality of care of HIV patients, 
in the private sector in developing countries, have highlighted some problems with management. In South Africa, two-thirds 
of doctors work in the private sector. Though many studies on HIV/AIDS have been undertaken, few have been done in 
the private sector in terms of the management of this disease. Therefore, a study was undertaken to evaluate the clinical 
management of HIV-infected patients by private sector doctors. 
Methods: A descriptive cross-sectional study was undertaken in the eThekwini Metro in KwaZulu-Natal, South Africa, 
with 190 private sector doctors who, in the first phase of the study, indicated that they manage HIV and AIDS patients and 
would be willing to participate in the second phase of the study. The HIV guidelines of the Department of Health and Human 
Services and the South African National Department of Health were used to compare the treatment of HIV patients by these 
doctors.
Results: Eighty-five doctors (54.5%) always measured the CD4 count and viral load levels at diagnosis. Both CD4 counts 
and viral load were always used by 76 doctors (61.8%) to initiate therapy. Of the doctors, 134 (78.5%) initiated therapy 
at CD4 count < 200 cells/mm3. The majority of doctors prescribed triple therapy regimens using the 2 NRTI + 1 NNRTI 
combination. Doctors who utilised CD4 counts tended to also use viral load (VL) to assess effectiveness and change 
therapy (p < 0.001). At initiation of treatment, 68.5% of the doctors saw their patients monthly and 64.3% saw them every 
three to six months, when stable. 
Conclusion: The majority of private sector doctors were compliant with current guidelines for HIV management, hence 
maintaining an acceptable quality of clinical healthcare.
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introduction
In the developing world, there are inadequate numbers of 
clinicians to assist in the management of the large number 
of patients with human immunodeficiency virus (HIV) and 
acquired immunodeficiency syndrome (AIDS), resulting in 
high mortality and morbidity rates and having major social 
consequences.1 The HIV/AIDS/tuberculosis (TB) epidemic 
has severely affected South Africa and, although the 
country has the largest public sector antiretroviral (ARV) 
programme in the world, it is unable to meet the needs of 
the high number of people infected.2 The most recent report 
on HIV prevalence amongst antenatal clinic attendees 
indicates that the province of KwaZulu-Natal remains the 
epicentre of the epidemic, with a prevalence of 38.7%.3 
The unequal distribution of resources between the public 
and private health sectors results in half of nurses and two-
thirds of doctors working in the private sector.4 In 2008, it 
was reported that there were more than 4 000 doctor posts 
vacant in state hospitals.5 We need to scale up access and 
use all available doctors, both in the public and private 
sector, to manage this epidemic. However, in KwaZulu-
Natal little is known about the practices of private sector 
doctors and whether these doctors manage their HIV/AIDS 
patients appropriately in accordance with international and 
national guidelines.6,7 
The United States Department of Health and Human 
Services panel (DHHS) developed guidelines to help 
clinicians treat adults and adolescents infected with HIV. 
The primary areas of attention and revision were when to 
initiate therapy, which drug combinations were preferred 
and which drugs or combinations should be avoided.6 
In formulating its guidelines, the South African National 
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Department of Health (NDOH) adopted continuum of care, 
with a holistic patient focus in an integrated health system. 
These guidelines were revised in order to ensure the highest 
possible standard of care for all South Africans.7
Private sector doctors are the backbone of treatment 
service in many countries; however, caring for patients with 
HIV entails a whole new set of challenges and difficulties.8 
The few studies done on the quality of care of patients with 
AIDS in the private sector in developing countries have 
highlighted some problems with management.9 In an Indian 
study, it was concluded that private practitioners were 
actively involved in diagnosing and managing patients with 
HIV/AIDS, but that some of their management practices 
were inappropriate and needed to be remedied.10 Anecdotal 
evidence from doctors in Lesotho suggests that the 
problem of poor management is widespread: only six of 24 
patients who were managed by private sector doctors were 
taking either mono- or dual therapy, while another patient 
was prescribed just ten doses of nevirapine only instead of 
nevirapine in combination with other drugs taken for life.9 
Possible reasons cited were affordability, in that the doctor 
had prescribed what the patient could afford, and lack of 
knowledge on the part of the doctors.9 In a study done 
in Harare a decade ago, to gather data to help formulate 
treatment guidelines, there appeared to be therapeutic 
anarchy in the private sector in the way that antiretrovirals 
were used.11 The monitoring practices were also of concern 
in Uganda, where a survey of 21 private medical facilities 
reported that only four of 17 facilities which prescribed 
antiretroviral drugs had received CD4 and viral load (VL) 
results in the previous two months, for only 38 of the 340 
patients they were monitoring.12
Despite the fact that antiretroviral drugs have been available 
in the South African private healthcare sector since 1996, 
and although KwaZulu-Natal is the province with the 
highest HIV prevalence rate, all doctors in the private sector 
in KwaZulu-Natal are not managing HIV/AIDS patients. 
Possible reasons for this may be the lack of training, 
complexity of the regimens, and poor infrastructure, which 
cause many doctors to refer such patients to specialists.13 
Though many studies on HIV/AIDS have been undertaken, 
few have been done in the private sector in terms of the 
doctors’ compliance to guidelines on the management of 
HIV-infected patients and the quality of care provided to 
HIV/AIDS patients. This study was, therefore, undertaken to 
evaluate the clinical management of HIV-infected patients 
in the private sector in the eThekwini Metro, KwaZulu-Natal. 
Methods
A descriptive cross-sectional study was conducted 
amongst 190 private general practitioners (GPs) and 
specialists working in the eThekwini Metro, KwaZulu-Natal 
after obtaining their consent to be part of the study.
A comprehensive list of 1 255 GPs and specialists practising 
in the eThekwini Metro was obtained from the Medpages 
Directory; the KwaZulu-Natal Managed Care Coalition 
(KZNMCC), which is a private doctors’ grouping; the private 
doctors’ guilds; the Lancet Clinic Courier database; and the 
Southern African HIV Clinicians Society. In the first phase 
of the study, a valid sample of 931 doctors was obtained.13 
Of these, 235 doctors responded that they manage HIV and 
AIDS patients.13 Of the 235 doctors, 190 agreed to participate 
in the second phase of the study. These GPs and specialists 
were independent of any funding from the Government and 
were remunerated either by patients paying cash or via a 
medical aid. A semistructured anonymous questionnaire 
was completed by each of these doctors. Demographic 
information, initiation of ARV medication, laboratory markers 
and values used to initiate treatment, and prescribed 
regimens were all topics included in the questionnaire. The 
DHHS and NDOH guidelines for the management of HIV/
AIDS patients were used to determine the extent of private 
sector doctors’ compliance to five processes, namely: 
1. Evaluations done at diagnosis and before initiating 
therapy for HIV-infected patients. 
2. Criteria used to initiate antiretroviral therapy (ART).
3. ART regimen.
4. Laboratory parameters used to monitor effectiveness 
and to change therapy.
5. Frequency of clinical and laboratory monitoring by these 
doctors. 
All information was treated confidentially. The completed 
questionnaires were collected, entered and analysed using 
SPSS Version 15. Frequency tables and percentages were 
used to describe the responses in the case of categorical 
variables. Cross-tabulations and Pearson’s chi-square test 
were used to assess associations between categorical 
variables, with a p-value < 0.05 indicating statistical 
significance. 
Ethics approval for the study protocol was obtained from 
the Nelson R Mandela School of Medicine, University of 
KwaZulu-Natal.
Results
A response rate of 90% (171) was obtained from the 190 
doctors, consisting of 138 (80.7%) GPs and 33 (19.3%) 
specialists. Compliance with the five processes is described 
below.
Evaluations at diagnosis of HIV-infected patients
Laboratory markers used at diagnosis:
CD4 count and VL were always measured by 119 doctors 
(76.3%) and 85 doctors (54.5%), respectively, at diagnosis 
of HIV/AIDS patients. All 85 doctors (54.5%) who always 
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measured VL at diagnosis also measured CD4. However, 
five doctors (3.2%) never measured CD4 or VL at diagnosis
Evaluations before initiating therapy
Complete medical history and physical examination 
(clinical assessment):
The majority of doctors (149, 96.1%) always clinically 
assessed their patients before initiating therapy, using 
indicators such as weight loss, opportunistic infections and 
fever. 
Laboratory tests:
1. Complete blood count: (n = 152)
A total of 138 doctors (90.8%) always or often did complete 
blood counts before initiating therapy. 
2. TB screening: (n = 148)
Some 123 doctors (83.1%) always or often screened for TB 
before initiating therapy. 
3. CD4 and VL measures: (n = 143)
A total of 123 doctors (86.0%) always measured CD4 and 
79 (55.2%) always measured VL before initiating therapy, of 
whom 76 doctors (61.8%) always used both CD4 counts 
and VL to initiate therapy.
The reasons cited by the doctors who did not always or 
often do blood counts, TB screening, VL and CD4 was that 
it was too costly for the patient. Some doctors also cited 
inadequate laboratory access as a reason for not doing 
TB screening. However, inadequate training or inadequate 
laboratory facilities did not deter doctors wanting to do 
laboratory evaluation before initiating therapy. 
Criteria for initiation of treatment
Of the 149 doctors, 117 (78.5%) doctors reported using 
CD4 count < 200 cells/mm3, and 24 (16.1%) reported using 
CD4 count < 350 cells/mm3 to initiate therapy.
Of the 90 respondents, 30 doctors (33.3%) initiated therapy 
at VL levels between 50 000 and 100 000, while 22 (24.4%) 
doctors did so at VL levels > 100 000. Two doctors stated 
that they would initiate therapy at any level if the patient 
requests therapy, while one doctor would initiate therapy at 
any level if the patient is pregnant.
Drug regimen
Antiretroviral treatment regimens:
A range of antiretroviral drugs was used in deciding on the 
ART regimen (see Table I). 
It is clear from Table I that the majority of the doctors used 
the listed drugs in triple therapy regimens rather than as 
single, dual or four-drug therapy regimens. The drugs 
lamivudine, stavudine, zidovudine, didanosine, efavirenz 
and nevirapine were the most common ARV drugs used in 
this triple regimen, although the protease inhibitors ritonavir, 
indinavir and lopinavir were also used. The drugs nevirapine, 
zidovudine and stavudine appeared to be the only drugs 
used as single therapy. Only one doctor used tenofovir and 
this was used in a triple therapy regimen.  
The combinations of classes of drugs that were used in 
highly active antiretroviral therapy (HAART) are presented 
in Table II. 
Multiple regimens were used by doctors in order to treat 
different patients. In total there were 24 drug regimens from 
four different combination classes of antiretroviral drugs, 
Table I: Antiretroviral drugs used by private sector doctors in different regimens at initiation of treatment (n = 171)
Drug name
Drug class N = Single therapy Dual therapy Triple therapy Four-drug therapy
Count % Count % Count % Count %
Lamivudine (3TC) NRTI* 131 0 0% 11 8.4% 120 91.6% 0 0%
Stavudine (d4T) NRTI 97 1 1.0% 4 4.1% 89 91.8% 3 3.1%
Zidovudine NRTI 81 1 1.2% 9 11.1% 71 87.7% 0 0%
Didanosine (ddi) NRTI 48 0 0% 3 6.2% 45 93.8% 0 0%
Zalcitabine NRTI 11 0 0% 0 0% 9 81.8% 2 18.2%
Abacavir NRTI 5 0 0% 0 0% 4 80.0% 1 20.0%
Efavirenz NNRTI† 90 0 0% 5 5.6% 85 94.4% 0 0%
Nevirapine NNRTI 81 4 4.9% 4 4.9% 73 90.2% 0 0%
Tenofovir NtRTI‡ 1 0 0% 0 0% 1 100.0% 0 0%
Ritonavir PI§ 19 0 0% 0 0% 17 89.5% 2 10.5%
Indinavir PI 14 0 0% 0 0% 13 92.9% 1 7.1%
Lopinavir PI 13 0 0% 0 0% 12 92.3% 1 7.7%
Saquinavir PI 6 0 0% 1 16.7% 5 83.3% 0 0%
Nelfinavir PI 5 0 0% 0 0% 5 100.0% 0 0%
Atazanavir PI 4 0 0% 1 25.0% 1 25.0% 2 50.0%
* NRTI: nucleoside reverse transcriptase inhibitor     †NNRTI: non-nucleoside reverse transcriptase inhibitor     ‡ NtRTI: nucleotide reverse transcriptase inhibitor     § PI: protease inhibitor
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resulting in 619 reports by 171 doctors. The most common 
regimens used by the doctors were the 2 NRTI + 1 NNRTI 
regimen, followed by the 3 NRTI regimens. The 2 NRTI + 
Boosted PI was also used by a small minority of the doctors, 
while one doctor used tenofovir, an NtRTI with 2 NRTI.
Prophylaxis:
Of the doctors, 27 indicated the use of prophylaxis either 
in single therapy regimen (25.9%), dual therapy regimen 
(3.7%), triple-therapy regimen (55.6%) or only as prophylaxis 
(14.8%). Co-trimoxazole was the drug used as prophylaxis.
There were no statistically significant differences between 
GPs and specialists regarding either the regimen or type of 
drug used.
Monitoring practices to assess effectiveness and to 
change therapy (n = 171)
Parameters used to monitor effectiveness of therapy:
1. Laboratory markers:
Table III depicts the frequency of combined use of laboratory 
markers by private sector doctors to monitor effectiveness 
of therapy of HIV/AIDS patients.
The CD4 count was used to monitor the effectiveness of 
therapy by the majority of doctors while 91 doctors (64.1%) 
used both CD4 counts and VL (see Table III). 
2. Clinical indicators:
A total of 138 doctors (80.7%) also assessed their patients 
clinically using weight loss and opportunistic infection as 
indicators. 
Parameters used to change therapy:
1. Laboratory markers:
In Table IV the combined use of laboratory markers to 
change therapy is shown.
Table II: Drugs used in combination therapy (HAART) by private sector 
doctors (n = 171)
 Drug regimen
No (%) of doctors that 
reported the use of 
different drug regimen 
(n = 171)











AZT+ddi+ nevirapine 25 (14.6%)
Total reports of drug 
regimen by doctors no 
(%), 95% CI
445 [71.9%(68.1–75.4)]





Total reports of drug 
regimen by doctors no 
(%), 95% CI
128 [20.7%(17.6–24.1)]
2 NRTI+1 NtRTI‡ 3TC+d4T+tenofovir 1 (0.6%)
Total reports of drug 
regimen by doctors no 
(%), 95% CI
1  [0.2%(0.01–1.04)]
2 NRTI+1 boosted PI§






Total reports of drug 
regimen by doctors no 
(%), 95% CI
45 [7.3%(5.41–9.68)]
Grand total 24 619
* NRTI: nucleoside reverse transcriptase inhibitor
† NNRTI: non-nucleoside reverse transcriptase inhibitor
‡ NtRTI: nucleotide reverse transcriptase inhibitor






Table III: The frequency of the combined use of CD4 and VL laboratory 
markers by private sector doctors to assess effectiveness of therapy of 
HIV/AIDS patients
 
No (%) of doctors 
that used VL levels to 
assess effectiveness  
of therapy
Total no of 
doctors
No Yes
No (%) of doctors that 
used CD4 counts to assess 
effectiveness of therapy  
No 24 (82.8%) 5 (17.2%) 29
Yes 51 (35.9%) 91 (64.1%) 142
Total no of doctors 75 (43.9%) 96 (56.1%) 171
 p < 0.001
Table IV: The frequency of the combined use of CD4 and VL laboratory 
markers by private sector doctors to change therapy of HIV/AIDS patients 
(n = 171) 
 
No (%) of doctors 
that used VL levels to 
change therapy
Total no of 
doctors
No Yes
No (%) of doctors that used 
CD4 counts to change 
therapy
No 36 (62.1%) 22 (37.9%) 58
Yes 17 (15.0%) 96 (85.0%) 113
Total no of doctors 53 (31.0%) 118 (69%) 171
 p < 0.001
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Ninety-six doctors (56.1%) used both CD4 and VL to 
change therapy while 22 (12.9%) doctors did not use CD4 
counts but used VL. 
The majority of the doctors changed therapy depending on 
the degree of change from the previous CD4 count (105, 
78.4%) and from the previous VL level (101, 81.5%). 
2. Clinical indicators and resistance testing:
A total of 101 (59.1%) doctors used clinical indicators such 
as weight loss and the presence of opportunistic infections 
to change therapy. 
Thirty-three doctors (19.3%) tested for resistance before 
they changed therapy. Two-thirds of these doctors also 
used CD4 count and VL to change therapy.
Frequency of clinical and laboratory monitoring of HIV-
infected patients
Frequency of doctor consults with HIV-infected 
patients:
1. When treatment was initiated doctors saw their patients:
• every month: 100 (67.1%)
• every second month: 8  (5.4%)
• every three months: 18 (12.1%)
• every four to six months: 3 (2%)
• every seven to 12 months: 2 (1.3%)
• at the patient’s request: 6 (4%)
• depending on clinical status: 12 (8.1%)
2. When patients were stable doctors saw them:
• every month: 18 (12.5%)
• every second month: 10 (6.9%)
• every three months: 56 (38.9%)
• every four to six months: 37 (25.7%)
• every seven to 12 months: 19 (13.2%)
• at the patient’s request: 4 (2.8%)
Twelve doctors saw their patients as frequently as required 
depending on their clinical status, but when patients were 
stable 50.0% saw them every three months.
Frequency of laboratory monitoring:
CD4 (n = 151): 
Most doctors (122, 80.8%) monitored for CD4 every three 
to six months, while 17 (11.3%) monitored every eight to 12 
weeks. Four doctors (2.6%) reported no CD4 monitoring. 
VL (n = 132):
A total of 65 doctors (49.2%) monitored the VL levels at 
six months, while 41 doctors (31.1%) monitored VL every 
three to four months. Six doctors (4.5%) indicated no VL 
monitoring. 
Referral practices of private sector doctors (n = 171)
Over 76% of doctors referred HIV/AIDS patients to the next 
level of care, and the majority (70%) stated that they do this 
when patients are very ill. However, over 45.6% of doctors 
referred patients on request and 41.8% of doctors referred 
patients due to drug failure. The doctors referred patients 
to specialists (61.2%) as well as to public sector (58.8%) or 
parastatal health facilities (32.5%).
Compliance with guidelines (n = 145) 
The majority (133, 91.7%) of doctors stated that they follow 
guidelines in the management of HIV-infected patients. 
However, when asked to name the guidelines they followed 
36 (26.9%) doctors were not sure of the name, 51 (38.2%) 
stated that they followed the guidelines of the SA HIV 
Clinicians Society, 21 (15.73%) stated the NDOH guidelines 
and 25 (19%) named other sources. 
Therapeutic decision making (n = 159)
The majority of the doctors (88.1%) always engaged their 
HIV and AIDS patients in any therapeutic decision making 
concerning their clinical management.
A summary of the practices and guideline recommendations 
is depicted in Table V.
Discussion
This study evaluated five dimensions of the HIV/AIDS care 
of patients by private sector doctors, namely:
• the evaluations done at diagnosis and before initiating 
therapy for HIV-infected patients
• the criteria used to initiate ART
• the ART regimen
• the laboratory parameters that are used to monitor 
effectiveness and to change therapy
• the frequency of clinical and laboratory monitoring by 
these doctors. 
The DHHS and NDOH guidelines for the management of 
HIV/AIDS patients were used as comparators to determine 
the extent of compliance by private sector doctors, hence 
evaluating the quality of care these doctors provide to HIV-
infected patients.
The majority of the doctors complied with the recom-
mendations published in the guidelines with respect to the 
evaluations done at diagnosis and at the pre-treatment 
stage. The doctors in this study tended to make use of the 
CD4 counts more than they did of the VL at diagnosis and 
before initiating ART. However, when it came to changing 
therapy more doctors used the VL than the CD4, and more 
VL determinations were used to monitor effectiveness than 
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were used at diagnosis or initiation of treatment. Laboratory 
markers such as CD4 cells/mm3 and VL are cited in the 
guidelines as important parameters to initiate, assess and 
change therapy. The CD4 count normally decreases by 
30 to 100 cells/mm3 a year in an HIV-infected patient who 
is not on HIV medication14 and serves as a major clinical 
indicator of immuno-competence in patients with HIV 
infection.6 It is usually the most important consideration 
in decisions to initiate ARV therapy. VL is normally used 
as a consideration in the decision to initiate therapy6 but 
is critical for evaluating response to therapy since plasma 
VL has been shown to be a better predictor of progression 
to AIDS and death than the number of CD4+ T cells..15 
Interestingly only 19.3% of the doctors used resistance 
testing to change therapy. Resistance testing continues to 
be an important component of optimising drug selection 
after treatment failure. Resistance testing is recommended 
in all patients with virological failure prior to beginning a 
Table V: Summary of process indicators and doctor practices to evaluate compliance with guideline










Evaluation at diagnosis and before initiation of therapy DHHS NDOH
Clinical assessment R R 149 (96.1%) 155
CD4 R R 131 (86.2%) 152
VL R R 79 (55.2%) 143
TB screening R R 92 (62.2%) 124
Complete blood count R R 123 (80.9%) 152
Criteria for ARV initiation
Asymptomatic: CD4 < 200 cells/mm3 R R 117 (78.5%) 149
Asymptomatic: CD4 < 350 cells/mm3 R R 24 (16.1%) 149
VL > 100 000 R R 22 (24.4%) 90
ART regimen
Preferred classes of drug 
a. NNRTI-based regimens 
    [1NNRTI+2NRTI]
R R Used 71.9% 
b. PI-based regimens 
    [1 PI (boosted)]+2NRTI
R R Used 7.3%
c. Triple-NRTI regimens 
    [only if NNRTI and PI cannot be used]               
S Used 20.7%
Preferred drug regimen
a. Efavirenz+3TC+d4T R 61 (35.6%)
a. Nevirapine+3TC+d4T R 54 (31.6%)
a. Efavirenz+AZT+3TC 47 (27.5%)
b. Lopinavir/ritonavir+AZT+ddi R 7 (4.1%)
b. Lopinavir/ritonavir+AZT+3TC R 7 (4.1%)
c. Abacavir+AZT+3TC R 0 (0%)
Clinical and laboratory evaluation to assess effectiveness of 
therapy    
Clinical assessment R R 138 (80.7%) 171
CD4 R R 142 (83.0%) 171
VL R R 96 (56.1%) 171
Clinical and laboratory evaluation to change therapy
Clinical assessment R R 101 (59.1%) 171
CD4 R R 113 (66.1%) 171
VL R R 118 (69%) 171
Frequency of clinical and laboratory evaluation
Clinical assessment: 149
Every month from initiation of treatment for 3 months 100 (67.1%)
Every 3 months when stable R 56 (38.9%) 151
CD4 :         Every 3 to 6 months R R 122 (80.8%) 132
VL:            Every 6 months R 65 (49.2%)
Original Research: Evaluation of the clinical management of HIV-infected patients by private sector doctors Original Research: Evaluation of the clinical management of HIV-infected patients by private sector doctors
457 Vol 52 No 5SA Fam Pract 2010
new ARV combination.16 However, the cost of this method 
to change therapy limits its use. CD4 and VL sometimes 
are not good predictors to change therapy as the issue of 
non-adherence may be the reason for these values giving a 
non-optimal result. 
The criteria used by the doctors to initiate therapy with 
respect to CD4 count were also found to be compliant with 
national and international guidelines. The majority of the 
private sector doctors in this study initiated therapy when 
the CD4 count was less than 200 cells/mm3 while 16.1% 
initiated therapy at less than 350 cells/mm3. The medical 
criterion that was recommended to initiate ARV therapy 
was a CD4 cell count of equal to or less than 200 cells/
mm3 irrespective of World Health Organization (WHO) 
stage.7 The DHHS guidelines7 also recommended therapy 
initiation at CD4 counts of less than 350 cells/mm3; it is 
crucial, however, at critical levels of less than 200 cells/
mm3. The SA HIV Clinicians Society guidelines17 at the 
time also recommended ART treatment in asymptomatic 
patients with CD4 counts of less than 200 cells/mm3, and 
that ARV therapy should be considered on an individual 
basis in patients with CD4 counts between 200 and 350 
cells/mm3. The national guidelines at the time did not make 
any recommendation regarding initiating therapy at levels 
< 350 cells/mm3, therefore the minority of doctors in this 
study that initiated therapy at <  350 cells/mm3 could be 
clinicians that belonged to the SA HIV Clinicians Society 
or followed international guideline recommendations. At 
CD4 levels > 350 cells/mm3, the recommendation was that 
treatment should be deferred6,17 as there was little evidence 
on the benefit of initiating therapy in asymptomatic patients 
with CD4 cell count > 350 cells/mm3 as robust immune 
reconstitution still occurred in the majority of patients 
who initiated treatment with CD4 cell counts in the 200 to 
350 cells/mm3 range. Also, toxicity risks and adherence 
challenges generally outweigh the benefits of initiating 
therapy at CD4 cell counts > 350 cells/mm3.6 The DHHS 
guidelines recommend initiating therapy when the VL is 
above 100 000 in established HIV asymptomatic infection. 
In this study 22 doctors (24.4%) initiated therapy when the 
VL was > 100 000. 
The majority of the doctors in the private sector complied with 
the national and international guideline recommendations in 
treating with triple drug combination therapy, consisting of 
either 2 NRTI/NtRTI with 1 NNRTI or 1 boosted or unboosted 
PI.6,7,17 The most common regimen prescribed by doctors 
in this study was the triple therapy consisting of 2 NRTI + 
1 NNRTI, followed by 3 NRTI, and 2 NRTI + boosted PI. 
The drugs lamivudine (3TC) + stavudine (d4T) with either 
efavirenz or nevirapine were most commonly prescribed in 
the 2 NRTI + 1 NNRTI regimen. 
The NDOH guidelines for the first-line regimen for all public 
sector patients at the time was 3TC + d4T with either 
efavirenz or nevirapine unless contraindicated, and for 
the second-line regimen zidovudine (AZT) plus didanosine 
(ddi) and lopinavir/ritonavir (Kaletra®). This study found 
the first-line regimen to be the most commonly prescribed 
regimen by the private sector doctors, with only 7.1% 
prescribing the second-line regimen. Because of the 
scarcity of guidelines for HIV management in the private 
healthcare sector, these doctors may have opted to follow 
the guidelines recommended by the NDOH for first-line 
regimens. In addition, the SA HIV Clinicians Society also 
endorsed the use of NRTI and NNRTI as first-line regimen in 
their published guidelines.
The 3 NRTI combination was used more frequently than the 
recommended second-line regimen by the doctors in this 
study. The national guidelines do not make any reference 
to its use. The DHHS guidelines, however, recommend 
its use only when the first-line and second-line regimens 
have failed, but go on to suggest the drugs that need to be 
used in this combination.6 The SA HIV Clinicians Society 
recommends that patients be referred for specialist care 
if the first-line and second-line regimens fail and that 
clinicians should avoid using this combination in patients 
who have failed the PI-based combination. Even though 
this drug class was used over 20% of the time by doctors 
in the study, no single doctor used the recommended drugs 
in this combination.
The frequency at which clinical and laboratory monitoring 
was done by doctors also complied with recommendations 
found in the guidelines: more than two-thirds of the doctors 
saw their patients every month when they initiated therapy, 
and about 65% saw them every three to six months when 
stable. Twelve doctors saw their patients as frequently 
as required, depending on their clinical status. Over 
three-quarters of the doctors monitored their patients for 
adherence using, among other indicators, CD4 counts and 
VL. The CD4 monitoring every three to six months and 
the VL monitoring every six months were consistent with 
international and national guideline recommendations. 
In addition, the national guideline recommendation, that 
patients be seen every month for three months and then 
every three months for clinical assessments, was adopted 
by the doctors in the study for the management of their HIV-
infected patients. The NDOH also recommended referring 
patients to specialists when there was drug failure, which 
was heeded by 41.8% of the doctors in this study.
There appeared to be major compliance with the HIV 
management guidelines published by the NDOH and 
the DHHS, with some good clinical practices, such 
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as monitoring for adherence and involving patients in 
therapeutic decision making. The majority of the doctors 
in this study demonstrate compliance to the guidelines, 
thereby affording their patients quality management of their 
condition. However, the response of 171 private sector 
doctors to the study limits the generalisability of the data 
to all doctors in the private sector in South Africa, since 
the sample size was relatively small and confined to the 
eThekwini Metro in KwaZulu-Natal. Further, the reliability 
and validity of participants’ self-reporting is unknown.
Conclusion	and	recommendations
The majority of the doctors are managing their patients 
in accordance with the recommended national and 
international guidelines. However, some doctors are 
treating their patients with drug combinations that are not 
recommended as second-line regimen. These doctors run 
the risk of not providing quality healthcare to their patients 
and, therefore, need to attend continuous AIDS training 
workshops regularly, in order to demonstrate compliance 
to guidelines and provide much needed quality care to HIV-
infected patients. It is also recommended that a further 
study be conducted to compare the management of private 
sector doctors with the revised guidelines and do a further 
evaluation of the quality of their clinical care. 
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